Leiomyosarcoma in 2018 – where we are and where we need to go.
Good afternoon readers! Having recently teamed up with the National Leiomyosarcoma Foundation as an advisory board member, for this posting I thought we’d focus on leiomyosarcoma, including some of the most common questions coming in from patients, caretakers and providers.
Evidence level: Feltételezés / hírjelzés. Nincs önálló tudományos bizonyíték.
Related signals
- First-Line Chemotherapy Regimens for Advanced and Metastatic Leiomyosarcoma: Doxorubicin vs. Gemcitabine—A Systematic Review
- Leiomyosarcoma
- Eribulin versus dacarbazine in patients with leiomyosarcoma: subgroup analysis from a phase 3, open-label, randomised study
- Lineage-defined leiomyosarcoma subtypes emerge years before diagnosis and determine patient survival
- Immunotherapy-based salvage therapy in advanced soft tissue sarcoma after first-line chemotherapy: a retrospective single-center analysis with emphasis on undifferentiated pleomorphic sarcoma